Novocure Ltd Market Cap ($1.56 Billion)
Market Cap & Net Worth: Novocure Ltd (NVCR)
Novocure Ltd market cap. Novocure Ltd (NASDAQ:NVCR) has a market capitalization of $1.56 Billion ($1.56 Billion) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6817 globally and #2150 in its home market, demonstrating a -6.74% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Novocure Ltd's stock price $13.43 by its total outstanding shares 115820940 (115.82 Million). Also see Novocure Ltd (NVCR) cash flow conversion for how efficiently the company converts equity into cash flow.
Novocure Ltd Market Cap History (2015–2026)
Novocure Ltd market cap history from 2015 to 2026. Data shows change from $2.59 Billion to $1.56 Billion (-4.83% CAGR). Check today's stock price for Novocure Ltd for real-time trading data and today's change.
Index Memberships
Novocure Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.06% | #195 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #771 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.08% | #115 of 263 |
Weight: Novocure Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Novocure Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Novocure Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Novocure Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.29x
Novocure Ltd's market cap is 2.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $909.19 Million | $82.89 Million | -$131.84 Million | 10.97x | N/A |
| 2017 | $2.34 Billion | $177.03 Million | -$61.66 Million | 13.22x | N/A |
| 2018 | $3.88 Billion | $248.07 Million | -$63.56 Million | 15.63x | N/A |
| 2019 | $9.76 Billion | $351.32 Million | -$7.23 Million | 27.78x | N/A |
| 2020 | $20.04 Billion | $494.37 Million | $19.81 Million | 40.54x | 1011.80x |
| 2021 | $8.70 Billion | $535.03 Million | -$58.35 Million | 16.25x | N/A |
| 2022 | $8.50 Billion | $537.84 Million | -$92.53 Million | 15.80x | N/A |
| 2023 | $1.73 Billion | $509.34 Million | -$207.04 Million | 3.40x | N/A |
| 2024 | $3.45 Billion | $605.22 Million | -$168.63 Million | 5.70x | N/A |
| 2025 | $1.50 Billion | $655.35 Million | -$136.23 Million | 2.29x | N/A |
Competitor Companies of NVCR by Market Capitalization
Companies near Novocure Ltd in the global market cap rankings as of November 5, 2026. Also see balance sheet size of Novocure Ltd for a full breakdown of the balance sheet.
Key companies related to Novocure Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #110 globally with a market cap of $190.23 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #204 globally with a market cap of $119.12 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #226 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #110 | Abbott Laboratories | NYSE:ABT | $190.23 Billion | $109.40 |
| #204 | Stryker Corporation | NYSE:SYK | $119.12 Billion | $310.55 |
| #226 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $98.88 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Novocure Ltd (2015–2026)
Market capitalization of Novocure Ltd from 2015 to today. Between 2015 and today, Novocure Ltd's market cap moved from $2.59 Billion to $ 1.56 Billion, with a yearly change of -4.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.56 Billion | +3.87% |
| 2025 | $1.50 Billion | -56.61% |
| 2024 | $3.45 Billion | +99.60% |
| 2023 | $1.73 Billion | -79.65% |
| 2022 | $8.50 Billion | -2.30% |
| 2021 | $8.70 Billion | -56.61% |
| 2020 | $20.04 Billion | +105.34% |
| 2019 | $9.76 Billion | +151.70% |
| 2018 | $3.88 Billion | +65.74% |
| 2017 | $2.34 Billion | +157.32% |
| 2016 | $909.19 Million | -64.89% |
| 2015 | $2.59 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Novocure Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.56 Billion USD |
| MoneyControl | $1.56 Billion USD |
| MarketWatch | $1.56 Billion USD |
| marketcap.company | $1.56 Billion USD |
| Reuters | $1.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TT… Read more